Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 18501093)

  • 1. Advances in genomic and proteomic studies of non-small-cell lung cancer: clinical and translational research perspective.
    Dziadziuszko R; Hirsch FR
    Clin Lung Cancer; 2008 Mar; 9(2):78-84. PubMed ID: 18501093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer.
    Miura N; Nakamura H; Sato R; Tsukamoto T; Harada T; Takahashi S; Adachi Y; Shomori K; Sano A; Kishimoto Y; Ito H; Hasegawa J; Shiota G
    Cancer Sci; 2006 Dec; 97(12):1366-73. PubMed ID: 17052260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individualized therapy in non-small-cell lung cancer: future versus current clinical practice.
    Pérez-Soler R
    Oncogene; 2009 Aug; 28 Suppl 1():S38-45. PubMed ID: 19680295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular predictors of chemotherapy response in non-small-cell lung cancer.
    Gray J; Simon G; Bepler G
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):545-9. PubMed ID: 17428174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospects for molecular staging of non-small-cell lung cancer from genomic alterations.
    Tomaszek SC; Huebner M; Wigle DA
    Expert Rev Respir Med; 2010 Aug; 4(4):499-508. PubMed ID: 20658911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The emerging role of biomarkers in advanced non-small-cell lung cancer.
    Socinski MA
    Clin Lung Cancer; 2010 May; 11(3):149-59. PubMed ID: 20439190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological markers in lung cancer: A clinician's perspective.
    Tufman A; Huber RM
    Cancer Biomark; 2010; 6(3-4):123-35. PubMed ID: 20660959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular biologic staging of lung cancer.
    D'Amico TA
    Ann Thorac Surg; 2008 Feb; 85(2):S737-42. PubMed ID: 18222207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A; Sørensen JB
    Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.
    Kancha RK; von Bubnoff N; Peschel C; Duyster J
    Clin Cancer Res; 2009 Jan; 15(2):460-7. PubMed ID: 19147750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translational research in lung cancer.
    Chen Y; Okunieff P; Ahrendt SA
    Semin Surg Oncol; 2003; 21(3):205-19. PubMed ID: 14508854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer.
    Sève P; Reiman T; Dumontet C
    Lung Cancer; 2010 Feb; 67(2):136-43. PubMed ID: 19828208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer.
    Okuda K; Sasaki H; Dumontet C; Kawano O; Yukiue H; Yokoyama T; Yano M; Fujii Y
    Lung Cancer; 2008 Oct; 62(1):105-12. PubMed ID: 18395930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression profiling of non-small-cell lung cancer.
    Lacroix L; Commo F; Soria JC
    Expert Rev Mol Diagn; 2008 Mar; 8(2):167-78. PubMed ID: 18366303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the prognostic role of a panel of biomarkers in stage IB-IIIA non-small cell lung cancer patients.
    Timotheadou E; Skarlos DV; Samantas E; Papadopoulos S; Murray S; Skrickova J; Christodoulou C; Papakostantinou C; Pectasides D; Papakostas P; Kaplanova J; Vrettou E; Karina M; Kosmidis P; Fountzilas G
    Anticancer Res; 2007; 27(6C):4481-9. PubMed ID: 18214064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGF receptor in lung cancer: a successful story of targeted therapy.
    Domingo G; Perez CA; Velez M; Cudris J; Raez LE; Santos ES
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1577-87. PubMed ID: 20942629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic medicine in non-small cell lung cancer: paving the path to personalized care.
    Sriram KB; Larsen JE; Yang IA; Bowman RV; Fong KM
    Respirology; 2011 Feb; 16(2):257-63. PubMed ID: 21044232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization--why, when, and how?
    Dziadziuszko R; Hirsch FR; Varella-Garcia M; Bunn PA
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4409s-4415s. PubMed ID: 16857819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The biology of epidermal growth factor receptor in lung cancer.
    Scagliotti GV; Selvaggi G; Novello S; Hirsch FR
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4227s-4232s. PubMed ID: 15217963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
    Crawford J
    J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.